Every 8-K that Parabilis Medicines, Inc. (PBLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PBLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBLS filings page.
Parabilis Medicines, Inc. (PBLS) reports that it plans to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The oral presentation is scheduled for Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45 p.m. CEST (8:45 a.m. ET). The company characterizes this disclosure as furnished under a Regulation FD-related item, not filed for liability purposes under the Exchange Act.
Parabilis Medicines, Inc. (PBLS) reports that Chief Medical Officer Fawzi Benzaghou, M.D. will transition from the company. The company and Dr. Benzaghou mutually agreed to his departure on August 28, 2026, with his service ending effective September 30, 2026.
In connection with this transition, Dr. Benzaghou is entitled to receive severance benefits in accordance with the terms of his existing employment agreement with Parabilis Medicines.
Parabilis Medicines, Inc. (PBLS) expanded its Board of Directors to nine members and appointed Craig L. Tendler, M.D. as a Class II director, with his term running until the 2028 annual meeting of stockholders. The Board determined that he is independent under Nasdaq listing standards and named him to the Science & Technology Committee. As part of the non-employee director compensation program, he received a stock option to purchase 20,294 shares at an exercise price of $39.36 per share, vesting in 36 equal monthly installments over three years while he remains on the Board, plus annual cash retainers of $40,000 for Board service and $7,500 for Science & Technology Committee service, paid quarterly and pro rated. Parabilis highlighted Dr. Tendler’s more than 30 years of oncology drug development and medical affairs experience, including leadership roles at Johnson & Johnson contributing to over 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations and approvals for 15 New Molecular Entities, and positioned his expertise as complementary to its Helicon peptide platform and lead candidate zolucatetide.
Parabilis Medicines, Inc. reported second-quarter 2026 results and major strategic developments. The company closed an upsized initial public offering raising $770.5 million at $20.00 per share and completed a concurrent $75 million private placement with Regeneron. Parabilis ended June 30, 2026 with $1.1 billion in cash, cash equivalents and marketable securities, which it expects will fund operations into 2030.
Parabilis announced a strategic collaboration with Regeneron for Antibody-Helicon Conjugates, receiving $125 million in upfront and equity consideration and the potential for up to $2.2 billion in milestones plus tiered royalties. The lead Helicon, zolucatetide, is advancing toward a planned Phase 3 registrational trial in desmoid tumors in the first half of 2027, with additional clinical milestones in familial adenomatous polyposis, adamantinomatous craniopharyngioma and other Wnt/β‑catenin–driven tumors.
For the quarter ended June 30, 2026, collaboration revenue was $148,000. Research and development expenses were $39.4 million and general and administrative expenses were $11.7 million, leading to a net loss of $52.5 million versus $34.8 million a year earlier, primarily due to higher operating costs as programs and public-company infrastructure expanded.
Parabilis Medicines, Inc. entered into a stock purchase agreement with Regeneron Pharmaceuticals, Inc., under which Regeneron bought 4,166,666 shares of Parabilis voting common stock in a private placement completed alongside Parabilis’ initial public offering at a per share price equal to 90% of the IPO price of $20.00.
The shares were issued as unregistered securities under Section 4(a)(2) of the Securities Act to an institutional accredited investor and include piggyback registration rights for Regeneron. Parabilis also put in place a seventh amended and restated certificate of incorporation authorizing 800,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock, and updated its bylaws to align governance, including stockholder meeting and director nomination procedures, with its new public-company structure.